相关实验视频

Updated: Sep 18, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

分子动力学模拟血抗叶剂药物协同作用在癌症治疗中的模拟

Yanxiong Niu¹, Tong Zhao¹, Xiaolong Wang¹

¹School of Electrical Engineering, Shandong University, Ji'nan 250061, China.

|June 26, 2025

概括

冷大气等离子体 (CAP) 通过氧化叶酸载体hSLC19A1.1.损害癌细胞. 这会损害叶酸的吸收,增强化学疗法药物的疗效,如美 (PMX) 诱导癌细胞死亡.

科学领域:

生物物理学的生物物理.
计算化学的计算化学
癌症治疗癌症治疗

背景情况:

冷大气等离子体 (CAP) 通过产生活性氧物种 (ROS) 来诱导癌细胞亡.
癌细胞依赖于抗氧化剂防御系统,包括通过hSLC19A1吸收叶酸以产生NADPH,以生存.
干扰叶酸运输是一种潜在的策略,可以提高化疗对抗癌症的疗效.

研究的目的:

为了研究等离子体诱导的氧化对hSLC19A1载体的影响.
了解氧化如何影响hSLC19A1.1.通过hSLC19A1.1.通过hSLC19A1.1.通过hSLC19A1.1.通过hSLC19A1.1.通过hSLC19A1.通过hSLC19A1.通过hSLC19A1.通过hSLC19A1.
为CAP介导的癌细胞亡提供理论见解.

主要方法:

经典的分子动力学模拟被用来建模hSLC19A1传送器.
该研究模拟了血氧化对hsLC19A1与5-MTHF和PMX的相互作用的影响.
进行了对接亲和和结合能量的计算,以量化分子相互作用.

主要成果:

氧化缩小了hSLC19A1通道,阻碍了5-MTHF的运输,并降低了它的结合亲和力.
氧化修饰降低了hSLC19A1和5-MTHF之间的结合能量,而PMX结合保持稳定.
这些变化表明氧化会削弱癌细胞的抗氧化防御,促进PMX诱导的亡.

结论:

血中hSLC19A1的氧化损害了叶酸的吸收,削弱了癌细胞的抗氧化防御.
这种机制增强了CAP和pemetrexed (PMX) 在诱导癌细胞亡方面的协同作用.
这些发现提供了对CAP抗癌机制的微观见解,支持其治疗发展.

关键词:

5-MTHF是一种5MTHF.hSLC19A1 一个问题.分子动力学模拟模拟在Pemetrexed中使用Pemetrexed.血辅助的癌症治疗疗法

更多相关视频

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...